# Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy

> **NCT03242265** · NA · TERMINATED · sponsor: **ATGen Canada Inc** · enrollment: 84 (actual)

## Conditions studied

- Immunity, Innate
- Prostatic Neoplasm

## Interventions

- **DIAGNOSTIC_TEST:** IVDD for NK cell activity in whole blood

## Key facts

- **NCT ID:** NCT03242265
- **Lead sponsor:** ATGen Canada Inc
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-04
- **Primary completion:** 2019-03-20
- **Final completion:** 2019-03-20
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03242265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03242265, "Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03242265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*